Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015340 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
A Phase 4 study of Substance-Related Disorders and Opioid Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 582
- Enrollment target
- 5
- Study locations
NCT00015340: Completed Phase 4 study of Substance-Related Disorders and Opioid Dependence, sponsored by National Institute on Drug Abuse (NIDA).
NCT00015340 is a Phase 4 study of Substance-Related Disorders and Opioid Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 582 participants, below the 1,511-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015340, a Phase 4 study of Substance-Related Disorders and Opioid Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 582 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.
Conditions Studied
Interventions
- DRUG Buprenorphine/naloxone
Study Locations (5)
California
- University of California - Los Angeles
Florida
- VA Medical Center - Tampa
Illinois
- VA Medical Center - Hines
New York
- New York VAMC - New York
Washington
- VA PUget Sound Helath Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 1999-08 |
| Est. Completion | 2001-09 |
| Phase | Phase 4 |
What the finished NCT00015340 record still lists
NCT00015340 is an interventional study that assigns participants to a tested intervention. The registered 582 participants enrollment target is mid-sized for trials with a published cap, below the 1,511-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00015340 lists 5 locations in 5 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT00015340 about?
NCT00015340 is a clinical study titled "Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14". The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.
What is the current status of trial NCT00015340?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 582 participants. The study started on 1999-08. Estimated completion is 2001-09.
What conditions does trial NCT00015340 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid Dependence.
What interventions are being tested in trial NCT00015340?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00015340?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015340 being conducted?
This trial has 5 study locations across California, Florida, Illinois, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00015340's enrollment target sits among peer trials
582 8th of 58 higher than 51 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Quetiapine for Cocaine Use and Cravings
COMPLETED · Phase 4
-
Relapse Prevention With Varenicline
COMPLETED · Phase 4
-
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia